José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Charité
Berlín, AlemaniaPublications en collaboration avec des chercheurs de Charité (12)
2023
2022
-
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Leukemia, Vol. 36, Núm. 7, pp. 1825-1833
-
CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S295-S296
2021
-
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Blood, Vol. 138, Núm. 21, pp. 2031-2041
-
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Leukemia, Vol. 35, Núm. 5, pp. 1344-1355
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
2019
-
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1589-1599
2018
-
Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial
Journal of Clinical Oncology, Vol. 36, Núm. 3, pp. 231-237
-
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
Journal of Cancer Research and Clinical Oncology, Vol. 144, Núm. 5, pp. 945-954
2017
-
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
Journal of Cancer Research and Clinical Oncology, Vol. 143, Núm. 7, pp. 1225-1233
-
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study
Leukemia, Vol. 31, Núm. 7, pp. 1525-1531
2016
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia, Vol. 30, Núm. 8, pp. 1648-1671